ConceptMedicine
Randomization
A process ensuring participants have an equal chance of being assigned to any study group to minimize bias and confounding.
Know first
Named as a prerequisite by the lectures that define this. The number is how many say so. A grey one has no page yet.
Opens up
Concepts that name this one as a prerequisite.
Lecturers
3Each in their own terms, from the easiest level.
Shrikant I. Bangdiwala
The process by which we control the confounders by ensuring that in a large number of people, the distribution of confounders in the intervention arm is similar to the controller arm.CEU CMC Vellore
The process that allows objective assignment of interventions and deals with confounders in a study.
Lectures that assume it
22The first 12 are shown.
- Nash Equilibrium: Location, segregation and randomization
- Is It Possible to Deliver Quality Education to the Poor? The Pratham-JPAL Partnership
- Interactive Proofs: IP=PSPACE
- CRITICAL APPRAISAL OF A RANDOMIZED CONTROL TRIAL _ DR THAMBU DAVID
- DEFINING THE STUDY OUTCOME _ DR SHRIKANT I BANGDIWALA
- TYPE OF HYPOTHESIS _ DR SHRIKANT BANGDIWALA
- TYPES OF ANALYSIS _ DR SHRIKANT BANGDIWALA
- PHASE I AND PHASE II DESIGNS _ DR MAHESH IYER
- COMMON RCT DESIGNS IN PHASE IIB AND III CLINICAL TRIALS - PART II _ DR. SHRIKANT I. BANGDIWALA
- Day 4 (III) - Case studies for early stopping: SHEPS _ Prof. Shrikant I Bangdiwala
- Day 5 - Community and environmental and policy trials _ Prof. Shrikant I Bangdiwala
- Day 3 (I) - End-of- study analyses_ Prof. Shrikant I Bangdiwala
Connections
34The lectures that define it or assume it, and the concepts next to it.
Concepts8
- Clinical trials
- Confounder
- Confounding
- Allocation concealment
- Intention-to-treat analysis
- Adaptive allocation
Show 2 moreShow fewer
Lectures26
- OPERATIONAL DESIGN CONSIDERATIONS IN RCTS _ DR SHRIKANT I BANGDIWALA
- COMMON RCT DESIGNS IN PHASE IIB AND III CLINICAL TRIALS - PART I _ DR. SHRIKANT I. BANGDIWALA
- Experimental Study Designs
- Day 1 (I) - Why do we need clinical trials _ Prof. SI Bangdiwala
- Nash Equilibrium: Location, segregation and randomization
- Is It Possible to Deliver Quality Education to the Poor? The Pratham-JPAL Partnership
Show 20 moreShow fewer
- Interactive Proofs: IP=PSPACE
- CRITICAL APPRAISAL OF A RANDOMIZED CONTROL TRIAL _ DR THAMBU DAVID
- DEFINING THE STUDY OUTCOME _ DR SHRIKANT I BANGDIWALA
- TYPE OF HYPOTHESIS _ DR SHRIKANT BANGDIWALA
- TYPES OF ANALYSIS _ DR SHRIKANT BANGDIWALA
- PHASE I AND PHASE II DESIGNS _ DR MAHESH IYER
- COMMON RCT DESIGNS IN PHASE IIB AND III CLINICAL TRIALS - PART II _ DR. SHRIKANT I. BANGDIWALA
- Day 4 (III) - Case studies for early stopping: SHEPS _ Prof. Shrikant I Bangdiwala
- Day 5 - Community and environmental and policy trials _ Prof. Shrikant I Bangdiwala
- Day 3 (I) - End-of- study analyses_ Prof. Shrikant I Bangdiwala
- Day 1 (III) - Types of trials_ Prof. SI Bangdiwala
- Day 4 (V) - Systematic Review and Meta Analysis _ Prof. Thambu David
- Day 4 (IV) - AI, ML and Computer intensive methods in RCTs _ Prof. Shrikant I Bangdiwala
- Day 3 (IV) Crossover trials design and analysis_ Dr.Visalakshi
- Day 4 (II) - Adaptive Study designs _ Prof. Shrikant I Bangdiwala
- Day 2 (I) - Design and Data Considerations _ Ananta Bangdiwala
- Day 4 (I) - Who to Include in Analyses _ Prof. L.Jeyaseelan
- Review of Tenecteplase for Thrombolysis for Acute Ischemic Stroke
- Day 2 (III) - Study Conduct _ Kumar Balasubramanian
- Evolution of Thrombolytics and Thrombectomy